Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy

Simó, Rafael; Hernández, Cristina

doi:10.1007/s00125-008-0989-9

Cited by 189 publications

(144 citation statements)

References 63 publications

Supporting

Mentioning

128

Contrasting

Unclassified

Order By: Relevance

“…This historical trend reflects there not being a dramatic change in treatment options for glaucoma, as there has been for other chronic eye diseases. 21,22 Stratification of the sample by age revealed a clear relationship between the rate of MD loss worsening with older age. Patients over 70 years had considerably worse median rate of loss compared with younger patients.…”

Section: Discussionmentioning

confidence: 96%

Are rates of vision loss in patients in English glaucoma clinics slowing down over time? Trends from a decade of data

Boodhna

Saunders

Crabb

2015

Eye

View full text Add to dashboard Cite

Purpose To examine changes in rates of visual field (VF) progression in patients attending a sample of glaucoma clinics in England between 1999 and 2012. Methods An archive of 473 252 Humphrey VFs recorded across the UK was retrospectively examined. Distribution of rates recorded in the first half of the decade was compared with the second. The relationship between age and severity of MD loss at baseline with rates of loss and frequency of testing was examined. Results VF series from 18 926 eyes were analysed. Median rate of MD loss for the period before and after 2003 was − 0.11 and − 0.06 dB/year, respectively, but the proportion of eyes with medium or fast rates of MD loss remained constant. Median rate of MD loss in older (470 years) eyes was faster than that observed in younger (o60 years) eyes (−0.21 compared with − 0.01 dB/ year). Median rate of loss did not vary with severity of MD loss at baseline. Frequency of testing, typically carried out annually, did not vary by age, rate of loss or disease severity. Conclusions VFs of eyes treated in the first half of the decade deteriorated more rapidly than those in the second half. Several factors might explain these differences but average effects were small and there was no reduction in the proportion of rapidly progressing eyes over the decade. Older age and, to a lesser extent, worse VF damage at diagnosis are indicators for faster VF loss in clinics, but frequency of VF testing was similar for all patients.

show abstract

Section: Discussionmentioning

confidence: 96%

Are rates of vision loss in patients in English glaucoma clinics slowing down over time? Trends from a decade of data

Boodhna

Saunders

Crabb

2015

Eye

View full text Add to dashboard Cite

show abstract

“…It has the capacity to promote formation of collateral vessels that has role in ischemic injury and wound healing [82]. In the pathological states such as oxidative stress, the physiological roles of VEGF take the darker side and its excess activation leads to consequences like hyperpermeability of retinal membrane, angiogenesis [83]. These changes are responsible for visual loss in case of diabetic retinopathy (Figure 4).…”

Section: Oxidative Stress In the Development Of Microangiopathymentioning

confidence: 99%

An Insight in to the Pathogenesis of Diabetic Vascular Diseases: Role of Oxidative Stress and Antioxidants

Aditi¹,

Mahajan²,

Rawal³

et al. 2013

Pharm Anal Acta

View full text Add to dashboard Cite

“…A terapia antiVEGF, apesar de ainda necessitar de estudos clínicos e ter uso off-label na RD, é uma realidade na prática médica do tratamento dessa doença (58,59).…”

Section: Vegf E Doença Ocular No Diabetes Melitounclassified

Papel do fator de crescimento vascular endotelial na angiogênese e na retinopatia diabética

Valiatti

Crispim

Benfica

et al. 2011

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

A retinopatia diabética (RD) é uma complicação microvascular do diabetes melito, sendo importante causa de cegueira adquirida. Fatores angiogênicos, como o vascular endothelial growth factor (VEGF), estão envolvidos na patogênese da RD. O VEGF-A é uma citocina potente e multifuncional que atua por meio dos receptores VEGFR-1 e VEGFR-2 expressos no endotélio vascular causando aumento da permeabilidade vascular e estímulo à neovascularização em processos fisiológicos e patológicos. O VEGFR-2 é o principal mediador mitogênico, angiogênico e do aumento da permeabilidade vascular. Alguns polimorfismos do VEGF têm sido estudados na suscetibilidade e risco de progressão da RD. Importante associação entre o polimorfismo 634C/G e a presença de RD é relatada principalmente em relação ao alelo C. A homozigose CC estaria relacionada à RD proliferativa (RDP) e a níveis sérico e vítreo aumentados de VEGF, sugerindo que a presença do alelo C seja um fator de risco independente para RD. Os conhecimentos sobre o VEGF levaram ao desenvolvimento de agentes antiVEGF com o objetivo de inibir a neovascularização patológica e são uma realidade na prática médica do tratamento da RD.

show abstract

Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy

Abstract: Vascular endothelial growth factor (VEGF) plays a key role in the development of both proliferative diabetic retinopathy (PDR) and diabetic macular oedema (DMO).

Cited by 189 publications

References 63 publications

Are rates of vision loss in patients in English glaucoma clinics slowing down over time? Trends from a decade of data

Are rates of vision loss in patients in English glaucoma clinics slowing down over time? Trends from a decade of data

An Insight in to the Pathogenesis of Diabetic Vascular Diseases: Role of Oxidative Stress and Antioxidants

Papel do fator de crescimento vascular endotelial na angiogênese e na retinopatia diabética

Contact Info

Product

Resources

About